Analysis: UK-US pharmaceuticals trade deal could divert NHS funds and harm public health
By
Cross S, Claxton K, Hill A.
Summary
This article argues that the UK-US pharmaceuticals trade deal, announced on 1 December 2025, will harm public health by diverting billions of pounds from NHS funding to pay higher prices for branded medicines. The deal secures 0% tariffs on UK pharmaceutical exports to the US but commits the NHS to substantially higher expenditure on drugs through changes to pricing arrangements and health technology assessment. The authors contend that without a corresponding increase in NHS resources, this creates significant opportunity costs — meaning less funding for other healthcare services — directly leading to thousands of excess deaths. They frame medicine pricing decisions as fundamentally about resource allocation and population health outcomes.
Source
bskyAnalysis: UK-US pharmaceuticals trade deal could divert NHS funds and harm public healthbmj.comKey quotes
· 3 pulledIn publicly funded systems with finite budgets, higher spending in one area inevitably takes away the opportunity to spend elsewhere.
This makes decisions about medicine pricing fundamentally decisions about how healthcare resources are allocated, and who the shortfall in funding affects most.
Without a corresponding increase in available NHS resources, this will create substantial opportunity costs elsewhere, having a direct effect on population health.
You might also wanna read
The public health impact of the Medicines Patent Pool increases with the fragmentation of intellectual property rights
U.S. restrictions on Chinese biotech could harm patients, argues editorial
The article argues against U.S. efforts to restrict collaboration with China's biotechnology industry, framing it as an extension of the tec
economist.com·14d agoU.S. restrictions on Chinese biotech could harm patients, argues editorial
The article argues against U.S. efforts to restrict collaboration with China's biotechnology industry, framing it as an extension of the tec
The Economist·14d ago
Drugmakers Plan Price Increases on 350+ Medications Despite Government Pressure
Drugmakers plan to raise U.S. prices on at least 350 branded medications in 2026, including COVID, RSV, and shingles vaccines, as well as ca
reuters.com·6mo ago
NHS trusts fail to account for over £400m in medical student training funds, BMJ investigation finds
An investigation by The BMJ reveals that NHS trusts in England have failed to account for over £400 million (nearly a quarter) of the £1.7 b
bmj.com·11d ago
UK Health Security Agency: Over 25% Chance of New Pandemic Within 5 Years
The UK Health Security Agency (UKHSA) has published its first Health Security Risk Assessment (HSRA), warning that there is more than a 25%
mdsc.pe·11d ago
NYC Public Hospitals End Palantir Contract Amid UK Controversy Over Government Deals
New York City's public hospital system is ending its contract with Palantir, the controversial AI and data analytics firm, as the contract e
theguardian.com·3mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.